The trajectory of Sildenafil presents a interesting case for stakeholders in the pharmaceutical sector. While initially a blockbuster success, producing huge profits, the exclusivity expiration and the subsequent entry of generic competitors have significantly impacted revenue. This poses questions about the long-term profitability of analogous med